Want to see HK:2197 full AI Analyst Report?
Clover Biopharmaceuticals Ltd. (2197) AI Stock Analysis
Top Page
Clover Biopharmaceuticals Ltd.
(HKEX:2197)
The score is driven primarily by very weak financial performance (collapsed revenue, sustained losses, negative equity, and ongoing cash burn). Technicals also detract due to a clear downtrend (price below key moving averages and negative MACD), while valuation offers only modest support from a low P/E without dividend support and amid high fundamental risk.
Clover Biopharmaceuticals Ltd. (2197) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.62B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.00M
- Price to Earnings (P/E)
- 1.6
- Beta (1Y)
- 1.88
- Revenue Growth
- -99.15%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 257
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions....
How the Company Makes Money
Clover Biopharmaceuticals generates revenue primarily from the development and commercialization of vaccine products, alongside collaboration- and licensing-related income where applicable. Key revenue streams include: 1) Product sales (vaccines and...
Clover Biopharmaceuticals Ltd. Financial Statement Overview
Summary
Financials are extremely weak: revenue collapsed in 2025 (~93% down vs. 2024), profitability is deeply negative with negative gross profit and persistent net losses, shareholder equity is consistently negative (2022–2025), and operating/free cash flow are materially negative across 2021–2025—indicating ongoing cash burn and elevated funding/dilution risk.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 423.34K | 3.41M | 38.42M | 39.26M | 0 | 0 |
| Gross Profit | -38.52M | -23.85M | -672.94M | 24.24M | -475.64M | -66.27M |
| EBITDA | -250.68M | -221.24M | -914.52M | -45.07M | -2.34B | -2.21B |
| Net Income | 843.28M | -199.78M | -903.43M | -138.54M | -2.45B | -6.02B |
Balance Sheet | ||||||
| Total Assets | 241.79M | 458.12M | 812.74M | 2.10B | 4.69B | 5.35B |
| Cash, Cash Equivalents and Short-Term Investments | 104.77M | 286.15M | 427.53M | 766.26M | 1.64B | 2.87B |
| Total Debt | 2.08M | 10.62M | 89.64M | 334.45M | 354.37M | 67.92M |
| Total Liabilities | 1.04B | 2.26B | 2.45B | 2.83B | 5.36B | 4.13B |
| Stockholders Equity | -801.06M | -1.80B | -1.64B | -732.83M | -668.14M | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | -260.44M | -190.55M | -290.11M | -737.05M | -1.80B | -998.07M |
| Operating Cash Flow | -260.44M | -190.52M | -288.49M | -727.88M | -1.69B | -917.75M |
| Investing Cash Flow | -1.72M | -11.69K | 3.17M | -6.16M | -37.51M | 112.12M |
| Financing Cash Flow | -144.38M | -76.59M | -51.50M | -142.41M | 483.14M | 3.06B |
Clover Biopharmaceuticals Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.53, below the 50-day MA of 1.86, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 28.55 is Positive, neither overbought nor oversold. The STOCH value of 29.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2197.
Clover Biopharmaceuticals Ltd. Peers Comparison
Overall Rating
HK:699870Outperform
HK:269664.6Neutral- HK:219743Neutral
HK:213742Neutral
HK:217940Underperform
HK:666037Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 70Outperform | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2197 | 43Neutral | HKD 1.62B | 1.61 | -64.89% | ― | -99.15% | ― |
| HK:2137 | 42Neutral | HKD 708.65M | -3.48 | -7.32% | ― | ― | 51.71% |
| HK:2179 | 40Underperform | HKD 2.49B | -4.41 | -79.24% | ― | -82.46% | 41.19% |
| HK:6660 | 37Underperform | HKD 1.88B | -2.43 | -24.66% | ― | -18.45% | -151.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2197 | Clover Biopharmaceuticals Ltd. | 1.25 | -0.99 | -44.20% | |
| HK:2137 | Brii Biosciences Limited | 0.98 | -0.91 | -48.15% | |
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:2179 | Jiangsu Recbio Technology Co., Ltd. Class H | 4.00 | -2.99 | -42.78% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% | |
| HK:6660 | AIM Vaccine Co., Ltd. Class H | 1.53 | -2.33 | -60.23% |
Clover Biopharmaceuticals Ltd. Corporate Events
Clover Posts Strong Phase 2 Data for Combination Respiratory Vaccines in Older Adults
Clover Biopharmaceuticals reported positive preliminary Phase 2 data from an Australian trial of its combination respiratory vaccines SCB-1022 and SCB-1033 in adults aged 60 to 85. The vaccines, targeting RSV, hMPV and PIV3, generated robust neutrali...
Clover Biopharmaceuticals Swings to Profit on GAVI Gain as Cash Levels Tighten
Clover Biopharmaceuticals reported a sharp swing to profit for the six months ended June 30, 2026, posting net income of about RMB955 million versus a loss of RMB101 million a year earlier. The turnaround was driven mainly by a one-off accounting gai...
Clover Biopharmaceuticals Sets Board Meeting to Approve Interim Results and Consider Dividend
Clover Biopharmaceuticals has scheduled a board meeting for August 25, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also consider the potential declaration of an interim dividend, signaling a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026